CRCI invested in Sagent in 2010.

Sagent Holding Co. is a generic specialty injectable (“SIP”) pharmaceutical company targeting the US hospital and clinical markets, with manufacturing facilities in China and sales, marketing and distribution in the US. Founded in late 2006, Sagent leverages global R&D resources, US distribution and Chinese manufacturing to realize increased value along the supply chain and higher return on equity.

CRCI successfully exited this investment in November 2011, at 2.0x ROI and 25.5% IRR.